menu search

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies ROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development […] The post MaxCyte Signs Strategic Platform License with Catamaran B... Read More
Posted: Jan 3 2023, 21:05
Author Name: forextv
Views: 102215

Search within

Pages Search Results: